Table 1_Visfatin levels in pulmonary disease: a systematic review and meta-analysis.docx

BackgroundVisfatin has been demonstrated to have pro-inflammatory effects and is involved in several respiratory disorders, including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia. However, there are some inconsistent findings. This study aimed to assess the association between serum visfatin levels and COPD, pneumonia, asthma, interstitial lung disease (ILD), and bronchiectasis.
MethodsA systematic review and meta-analysis were conducted following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. PubMed, Scopus, and Web of Science databases were searched. Studies including a healthy control group and measuring serum visfatin in patients with COPD, asthma, pneumonia, bronchiectasis, or ILD were included. Stata 17 was used for data analysis.
ResultsFourteen studies were included. None of them were on bronchiectasis. The analysis showed no significant difference between the COPD group and healthy controls in terms of serum visfatin levels (effect size = −0.02, �CI: [−0.74, 0.69], p = 0.95). Similarly, analysis of visfatin levels in asthma studies showed no significant difference between patients and healthy controls (effect size = −1.51, �CI: [−6.82, 3.79], p = 0.58). However, Serum visfatin levels were significantly higher in pneumonia patients compared to healthy controls (effect size = 1.93, �CI: [0.91, 2.95], p < 0.01).
ConclusionCirculating levels of visfatin may be associated with pneumonia, but not COPD or asthma. However, there are still few studies on the levels of visfatin in COPD, asthma, and pneumonia patients, and there is a need for further investigation.
Systematic Review RegistrationPROSPERO, identifier (CRD42023441144).

背景 内脂素（visfatin）已被证实具有促炎作用，并参与多种呼吸系统疾病的发生发展，包括慢性阻塞性肺疾病（chronic obstructive pulmonary disease, COPD）、哮喘（asthma）及肺炎（pneumonia）。但目前相关研究结论尚存不一致之处。本研究旨在探讨血清内脂素水平与慢性阻塞性肺疾病、肺炎、哮喘、间质性肺疾病（interstitial lung disease, ILD）以及支气管扩张症之间的关联。

方法 本研究遵循《流行病学观察性研究Meta分析指南》（Meta-analysis of Observational Studies in Epidemiology, MOOSE）开展系统评价与Meta分析。检索PubMed、Scopus及Web of Science数据库，纳入包含健康对照组且检测了慢性阻塞性肺疾病、哮喘、肺炎、支气管扩张症或间质性肺疾病患者血清内脂素水平的研究。采用Stata 17软件进行数据分析。

结果 本研究共纳入14项研究，其中无针对支气管扩张症的相关研究。分析结果显示，慢性阻塞性肺疾病患者与健康对照组的血清内脂素水平无显著差异（效应量=−0.02，95%置信区间：[−0.74, 0.69]，p=0.95）。同样，针对哮喘相关研究的分析显示，哮喘患者与健康对照组的血清内脂素水平亦无显著差异（效应量=−1.51，95%置信区间：[−6.82, 3.79]，p=0.58）。但肺炎患者的血清内脂素水平显著高于健康对照组（效应量=1.93，95%置信区间：[0.91, 2.95]，p<0.01）。

结论 循环内脂素水平可能与肺炎存在关联，但与慢性阻塞性肺疾病或哮喘无明显关联。然而，目前针对慢性阻塞性肺疾病、哮喘及肺炎患者的内脂素水平相关研究仍较少，尚需开展进一步研究予以验证。

系统评价注册 本研究已在PROSPERO平台注册，注册号为CRD42023441144。